U.S. markets open in 1 hour 5 minutes
  • S&P Futures

    4,558.50
    +14.00 (+0.31%)
     
  • Dow Futures

    35,460.00
    +71.00 (+0.20%)
     
  • Nasdaq Futures

    15,671.75
    +84.50 (+0.54%)
     
  • Russell 2000 Futures

    2,259.10
    +9.60 (+0.43%)
     
  • Crude Oil

    81.81
    -0.85 (-1.03%)
     
  • Gold

    1,804.50
    +5.70 (+0.32%)
     
  • Silver

    24.16
    -0.03 (-0.13%)
     
  • EUR/USD

    1.1589
    -0.0017 (-0.15%)
     
  • 10-Yr Bond

    1.5290
    0.0000 (0.00%)
     
  • Vix

    16.67
    +0.69 (+4.32%)
     
  • GBP/USD

    1.3734
    -0.0008 (-0.06%)
     
  • USD/JPY

    113.6130
    -0.1970 (-0.17%)
     
  • BTC-USD

    61,102.78
    +2,155.12 (+3.66%)
     
  • CMC Crypto 200

    1,471.53
    -2.80 (-0.19%)
     
  • FTSE 100

    7,236.43
    -16.84 (-0.23%)
     
  • Nikkei 225

    28,820.09
    -278.15 (-0.96%)
     

Stryker's (SYK) Trauma & Extremities Arm Unveils New Product

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·4 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Stryker Corporation’s SYK Trauma & Extremities division recently introduced a Citrelock Tendon Fixation Device System, which offers surgeons a differentiated design through a tendon thread featuring Citregen -- a resorbable technology. Citregen, in particular, has chemical and mechanical qualities intended for orthopaedic surgical applications.

The company is expected to debut the Citrelock Tendon Fixation Device System at the American Orthopaedic Foot & Ankle Society (AOFAS) Annual Meeting from Sep 22 to Sep 25, 2021, in Charlotte, NC. In addition, the company will host a new product reception, highlighting the benefits of Citrelock alongside other recent Foot & Ankle portfolio additions.

Per management, the Citrelock Tendon Fixation Device System, armed with its innovative material technology and unique design, helps fulfill the requirement of a more predictable and effective bioresorbable material compared to what is available on the market at present.

The recent launch of Citrelock Tendon Fixation Device System is likely to bolster Stryker’s Foot & Ankle portfolio.

Citrelock Features in Detail

The Citrelock Tendon Fixation Device System utilizes Citregen’s unique material properties features to ease insertion and secure fixation without damaging the tendon during placement. Notably, Citregen adds to Stryker’s existing biomaterial portfolio and will be expanded for use in additional Stryker Trauma & Extremities indications in the future.

Zacks Investment Research
Zacks Investment Research


Image Source: Zacks Investment Research

The Citrelock Tendon Fixation Device System provides surgeons a controlled and homogeneous resorption process that prevents bulk degradation and chronic inflammation as well as compressive strength that is similar to cortical bone with a modulus comparable to cancellous bone, and material polymer structure that mimics the extracellular matrix protein network. It incorporates Citregen, which is made up of citrate, calcium, and phosphate molecules, inherent to the bone anatomy. During the healing process, Citregen maintains structural integrity while the implant is gradually replaced by host tissue over time.

Industry Prospects

Per a report published in MarketsandMarkets, the foot and ankle devices market is projected to see a CAGR of 6.4% by 2025. The growing trend of using bioresorbable implants and devices in reconstruction, which eliminates the need for surgery to remove devices, is one of the major reasons supporting market growth. Further, several benefits associated with foot and ankle devices and growing focus on the development of specialized products for various foot and ankle disorders and deformities by key players are among the other factors driving the market.

Given the substantial market prospects, the recent launch of Stryker’s Citrelock Tendon Fixation Device System seems strategic.

Notable Developments

During its earnings call for the second quarter of 2021, Stryker noted that organic sales growth for the quarter was 9.3%, which represented growth across all of the company’s major businesses compared to 2019. The strong quarterly performance was led by strength exhibited by Neurovascular, Mako, emergency care, sports medicine and U.S. shoulder and total ankle products.

Apart from this, the company reported that the combined Trauma and Extremities business, which includes Wright Medical, grew 7% during the second quarter compared to 2019 on double-digit growth in the U.S. Trauma and Upper Extremities businesses. The reopening of economies and continued success of key products such as T2 Alpha and the mini-frag plating system benefited the company’s Trauma arm. Meanwhile, the U.S. upper extremities business exhibited strong double-digit growth in the quarter owing to sustained strength in the reverse ARPA plastic portfolio.

Share Price Performance

The stock has outperformed its industry over the past year. It has rallied 30.5% compared with the industry’s 10.9% rise.

Zacks Rank and Key Picks

Currently, Stryker carries a Zacks Rank #3 (Hold).

A few better-ranked stocks from the Medical-Products industry include VAREX IMAGING VREX, Envista Holdings Corporation NVST and BellRing Brands, Inc. BRBR, each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

VAREX has a long-term earnings growth rate of 5%.

Envista Holdings has a long-term earnings growth rate of 27.4%.

BellRing Brands has a long-term earnings growth rate of 29.1%.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Stryker Corporation (SYK) : Free Stock Analysis Report

VAREX IMAGING (VREX) : Free Stock Analysis Report

Envista Holdings Corporation (NVST) : Free Stock Analysis Report

BellRing Brands, Inc. (BRBR) : Free Stock Analysis Report

To read this article on Zacks.com click here.